Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd (SENORES) last traded at ₹1,480, a market capitalisation of ₹6,817 crore, on a P/E of 53.9. Over the past 52 weeks the stock has ranged between ₹662 and ₹1,600. Senores Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹180 crore and net profit of ₹30 crore. The next scheduled event is an analyst meet on 25 Aug 2026. Figures are as of 25 Aug 2026 and are not real time.
Senores Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Senores Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹180 cr, up 30.4% from ₹138 cr a year earlier. Net profit was ₹30 cr, up 42.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 101 | 103 | 114 | 138 | 162 | 171 | 175 | 180 |
| Expenses | 77 | 77 | 95 | 104 | 112 | 121 | 128 | 126 |
| Operating profit | 23 | 26 | 19 | 34 | 50 | 50 | 47 | 54 |
| OPM % | 23% | 25% | 17% | 25% | 31% | 29% | 27% | 30% |
| Other income | 2 | 5 | 12 | 3 | 5 | 7 | 18 | 3 |
| Interest | 5 | 6 | 5 | 5 | 6 | 5 | 8 | 7 |
| Depreciation | 4 | 4 | 5 | 6 | 8 | 8 | 9 | 10 |
| Profit before tax | 16 | 20 | 21 | 26 | 41 | 45 | 47 | 39 |
| Tax % | 18% | 20% | 13% | 20% | 26% | 25% | 23% | 23% |
| Net profit | 13 | 16 | 18 | 21 | 30 | 34 | 37 | 30 |
| EPS (₹) | 3.86 | 3.73 | 3.87 | 4.28 | 7.03 | 6.87 | 6.86 | 6.67 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Senores Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 14 | 35 | 215 | 398 | 633 | 688 |
| Operating profit | 2 | 13 | 42 | 90 | 168 | 201 |
| OPM % | 14% | 36% | 19% | 23% | 27% | 29% |
| Net profit | 1 | 8 | 33 | 58 | 122 | 131 |
| EPS (₹) | 1.01 | 8.59 | 10.31 | 12.72 | 25.05 | 27.43 |
TTM is the trailing twelve months to the most recent quarter.
Senores Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 162%
- TTM
- 51%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 139%
- TTM
- 87%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- 111%
- 10 Years
- %
- 5 Years
- 14%
- 3 Years
- 14%
- Last Year
- 13%
Senores Pharmaceuticals Ltd shareholding pattern
Promoters held 45.82% at Jun 2026, broadly unchanged since Jun 2025. FIIs 6.62% and DIIs 9.77%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Promoters | 45.77% | 45.78% | 45.78% | 45.80% | 45.81% | 45.82% | 45.82% |
| FIIs | 4.25% | 4.17% | 3.66% | 4.28% | 3.35% | 3.64% | 6.62% |
| DIIs | 11.77% | 9.66% | 9.51% | 8.62% | 9.32% | 9.62% | 9.77% |
| Public | 38.20% | 40.39% | 41.03% | 41.30% | 41.54% | 40.92% | 37.78% |
| No. of shareholders | 49,518 | 37,653 | 36,389 | 34,917 | 34,401 | 34,126 | 36,498 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Senores Pharmaceuticals Ltd events
The next scheduled event is an analyst meet on 25 Aug 2026.
- Analyst meetInvestor Conference with Antique Stock Broking
See the full results calendar for every Indian company reporting in the next 30 days.
Senores Pharmaceuticals Ltd corporate filings
- Senores Pharmaceuticals Limited has informed the Exchange regarding giving corporate guarantee for credit facilities availed by Apnar Pharma Private Limited, Subsidiary of the Company from ....Company Updatelow impact
Cruxal's analysis: Senores Pharmaceuticals Limited has formally notified the exchange regarding the…
Read the full analysis - Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/ Institutional Investor Meet scheduled to be held on August 25, 2026Company Updatelow impact
Cruxal's analysis: Senores Pharmaceuticals Limited has announced an analyst and institutional investor…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhananjay BarotInsider Trading / SASTlow impact
Cruxal's analysis: Senores Pharmaceuticals Limited has disclosed an inter-se transfer of 30,000 equity…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ashokkumar Vijaysinh BarotInsider Trading / SASTlow impact
Cruxal's analysis: Senores Pharmaceuticals Limited has disclosed an inter-se transfer of 30,000 equity…
Read the full analysis - Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Postal BallotAGM/EGMmedium impact
Cruxal's analysis: Senores Pharmaceuticals Limited announced that its shareholders have approved all eight…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Senores Pharmaceuticals Ltd
Cruxal reads every Senores Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.